Groundbreaking Heart Disease Study Challenges What We Know About Lp(a)

Gil Carvalho
Gil Carvalho
Sep 30, 2026 • 7 min read

A highly anticipated clinical trial of an Lp(a)-lowering drug has reported a disappointing result, raising a major question in heart disease research: if lowering this particle does not significantly reduce cardiovascular events, have we misunderstood its role?

That is a reasonable question. But jumping from “this trial did not demonstrate a benefit” to “Lp(a) is harmless” goes much further than the evidence allows.

This is personal for me. My Lp(a) is high, and so is my mother’s and my sister’s. I would love for it to turn out to be nothing more than an innocent marker. But science does not bend to what would be convenient for us. We have to consider the whole picture, including the genetics, the limitations of the trial, and what we can do to protect ourselves while the research continues.

Key Takeaways

  • Pelacarsen did not significantly reduce the Lp(a)HORIZON trial’s primary combined cardiovascular outcome.
  • Multiple genetic studies still support a causal role for Lp(a) in cardiovascular disease.
  • Managing blood pressure, other atherogenic particles, and metabolic health remains important when Lp(a) is high.

What Is Lp(a), and Why Does It Matter?

Our blood contains tiny particles called lipoproteins. Their presence is completely normal. The problem arises when certain lipoproteins become trapped inside artery walls, contributing to plaque that can eventually lead to heart attacks and strokes.

These particles include remnants, LDL, and lipoprotein(a), usually written as Lp(a) and pronounced “LP little a.” The evidence leading up to this trial suggested that Lp(a) was a particularly concerning member of this family.

High Lp(a) is common, affecting roughly one in five people. For levels measured in nanomoles per liter, the commonly used categories discussed here are:

  • Below 75 nmol/L: generally considered the normal or lower-risk range.
  • 75 to 125 nmol/L: an intermediate or borderline range.
  • Above 125 nmol/L: considered high and associated with increased cardiovascular risk.

My level is about 180 nmol/L.

Lp(a) is strongly influenced by genetics, which explains why high levels run in families. Unlike LDL and remnant particles, Lp(a) is relatively resistant to lifestyle changes. There is no established lifestyle strategy that reliably takes someone with a level like mine down into the normal range.

That does not make lifestyle irrelevant. It means we need to distinguish between lowering Lp(a) itself and lowering our overall cardiovascular risk. Those are not the same thing.

What the Lp(a)HORIZON Trial Tested

For years, a crucial piece of evidence was missing: a randomized clinical trial showing that specifically lowering Lp(a) reduces cardiovascular events.

The Lp(a)HORIZON trial was designed to help answer that question. It enrolled more than 8,000 participants with elevated Lp(a) and established cardiovascular disease. Participants received either pelacarsen, a drug previously shown to lower Lp(a) by about 80%, or a placebo.

That is a powerful effect on a blood measurement. But the important question was whether it translated into fewer serious health problems.

The trial’s primary outcome combined four types of events:

  • Death from cardiovascular causes.
  • Nonfatal heart attack.
  • Nonfatal stroke.
  • Urgent coronary revascularization, a procedure to restore blood flow to the heart.

Revascularization can involve opening a narrowed artery with a balloon and placing a stent, or performing bypass surgery.

The reported topline results indicated that pelacarsen did not produce a statistically significant reduction in the primary combined outcome compared with placebo.

That is a failure to meet the trial’s main goal, not proof that the treatment groups were identical in every respect. At the time of this initial announcement, the full results had not yet been released. Those details matter for interpreting the finding.

Why the Result Was So Surprising

Drugs fail in clinical trials all the time. That is precisely why we test them instead of assuming that a promising mechanism guarantees a benefit.

Still, expectations for Lp(a)-lowering therapies were high. This result brings to mind another major disappointment in cardiovascular research: drugs developed to raise HDL cholesterol.

The lesson from HDL cholesterol

For decades, observational research has shown that people with higher HDL cholesterol generally have a lower risk of heart disease. That correlation inspired the development of therapies intended to raise HDL cholesterol and, hopefully, prevent cardiovascular events.

Some drugs raised HDL cholesterol substantially. Yet randomized trials largely failed to deliver the expected cardiovascular protection.

The lesson was that a marker of risk is not necessarily a cause of risk. HDL cholesterol levels can help describe someone’s risk without the cholesterol measurement itself being a useful treatment target.

It is understandable that some people have interpreted the pelacarsen result in the same way: perhaps Lp(a), too, is only a marker.

I suspect that interpretation is wrong. The reason is not simply that high Lp(a) correlates with more disease. We have another, much stronger line of evidence.

The Genetic Evidence Is Difficult to Dismiss

Observational associations alone can mislead us. People with different Lp(a) levels may differ in other ways that influence cardiovascular risk.

Genetic studies approach the question differently. Across multiple studies, variants in the LPA gene that raise Lp(a) levels are associated with higher cardiovascular risk. Variants that lower Lp(a) are associated with lower risk.

This is not one isolated finding involving one genetic variant. The pattern appears across multiple variants in the gene itself. One of the genetic studies informing this evidence illustrates the relationship between altered LPA function and coronary heart disease risk.

That repeated pattern is much harder to explain away than a simple correlation between a blood measurement and disease.

Genetic evidence also supports a causal role for LDL and remnant particles. For Lp(a) to turn out to be harmless would therefore require a striking exception: a related lipoprotein for which multiple genetic findings point toward causality, yet that conclusion is somehow wrong.

That is possible in principle. But it would be extraordinary.

My prediction is that Lp(a) will remain a causal cardiovascular risk factor, and that this trial will turn out to be a more complicated result than a simple rejection of that idea. That is a prediction, not a settled explanation. Other ongoing randomized trials of Lp(a)-lowering therapies will help test it.

How Could a Causal Risk Factor Produce a Negative Trial?

A clinical trial tests a particular treatment, in a particular population, over a particular period. It does not test every possible way of modifying a biological pathway.

Several possibilities could help reconcile the pelacarsen result with the genetic evidence. None should be mistaken for an established explanation.

1. The result could be specific to pelacarsen

A drug can successfully lower its intended target while having other effects elsewhere in the body. In principle, an off-target effect could offset the benefit of lowering Lp(a), leaving no net cardiovascular benefit.

We do not yet know whether that happened here. If other Lp(a)-lowering therapies reduce cardiovascular events, however, the question would shift toward what is different about pelacarsen.

2. Lifelong exposure is different from treatment later in life

Genetic studies reflect exposure over a lifetime. Someone born with a variant that raises Lp(a) may have accumulated 40 or 50 years of exposure by middle age.

A clinical trial generally changes that exposure for only a handful of years. Lowering Lp(a) for roughly five years is not equivalent to having lower Lp(a) from birth.

Perhaps Lp(a) needs to be lowered for longer, or treatment needs to begin earlier in the disease process.

There is an important counterpoint: LDL-lowering trials show substantial cardiovascular benefits over about five years, even when treatment starts relatively late in life. So timing cannot simply be assumed to explain this result. Lp(a) would have to differ in some meaningful way.

3. The trial asked about additional benefit on top of existing treatment

These participants already had cardiovascular disease, and many other risk factors were being treated. Lipid-lowering therapies reduced their LDL burden and, to some extent, remnants. Blood pressure was also being managed.

The question was therefore quite specific: does lowering Lp(a) provide additional protection when other major risk factors are already being addressed?

That is clinically important. But it is narrower than asking whether lifelong high Lp(a) contributes to the development of cardiovascular disease in the first place.

How I Manage My Risk With High Lp(a)

The practical question is what to do while scientists work through these uncertainties.

I cannot currently bring my Lp(a) into the normal range. So I focus on three other areas that influence my overall cardiovascular risk.

Keep blood pressure well controlled

Systolic blood pressure is the higher number in a blood pressure reading. The evidence discussed here supports lower cardiovascular risk with systolic pressure below 120 mm Hg.

Personally, I aim a little lower, below 110 when possible, because I have this additional risk factor. There is nothing magical about my personal target, and it is not a prescription for everyone.

The principle is to take blood pressure seriously and establish an appropriate target with a clinician, rather than automatically copying someone else’s numbers.

Keep the other artery-damaging particles low

ApoB is a useful measure because it reflects the combined burden of atherogenic particles, including LDL, remnants, and Lp(a).

My personal ApoB target is in the 50s or 60s, measured in milligrams per deciliter. Not everyone needs to aim that low. I am taking extra steps because of my elevated Lp(a).

The logic is straightforward: if I cannot yet lower one important contributor to risk, I can still work to reduce the others.

Maintain healthy body composition and stay active

I also try to avoid excess body fat through a healthy diet and regular exercise. For me, staying lean and active helps keep blood sugar and insulin resistance under control.

This is not an attempt to exercise away my Lp(a). It is an effort to reduce the other pressures contributing to cardiovascular risk.

Limited control over Lp(a) does not mean limited value from prevention. Managing blood pressure, other lipoproteins, and metabolic health remains worthwhile even if the Lp(a) measurement barely changes.

A Surprising Result, Not the Final Answer

The pelacarsen finding deserves serious attention. A highly anticipated trial did not demonstrate the cardiovascular benefit many researchers expected, and we should not minimize that disappointment.

But we should not discard the genetic evidence either. The responsible response is to examine the full results, consider the findings from other ongoing trials, and distinguish the performance of one treatment from the biological role of its target.

For people who already have arterial plaque, the question extends beyond preventing new events to whether existing plaque can regress. Research has explored approaches involving diet and exercise, but a disappointing Lp(a) trial does not settle that separate question.

For now, my approach is neither panic nor dismissal. I take high Lp(a) seriously, acknowledge what remains uncertain, and keep working on the risk factors I can change.

This article is for educational purposes and is not medical advice, diagnosis, or treatment. Discuss your Lp(a), blood pressure, ApoB, and individual treatment goals with a qualified healthcare professional.

Share

Nutrition Made Simple!

We break down nutrition and health research into practical food choices, clear explanations and evidence-based fact-checks.

© 2026 Nutrition Made Simple!
Powered by Convella